WallStSmart

Boston Scientific Corp (BSX)vsBrainsway Ltd (BWAY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 34615% more annual revenue ($21.07B vs $60.70M). BSX leads profitability with a 16.6% profit margin vs 15.6%. BSX trades at a lower P/E of 18.6x. BSX earns a higher WallStSmart Score of 60/100 (C+).

BSX

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.78

BWAY

Buy

51

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-13.3%)

Margin of Safety

-13.3%

Fair Value

$39.14

Current Price

$43.70

$4.56 premium

UndervaluedFair: $39.14Overvalued

Intrinsic value data unavailable for BWAY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX3 strengths · Avg: 8.3/10
Market CapQuality
$64.07B9/10

Large-cap with strong market position

PEG RatioValuation
0.768/10

Growing faster than its price suggests

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

BWAY3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.4%10/10

Revenue surging 35.4% year-over-year

EPS GrowthGrowth
59.8%10/10

Earnings expanding 59.8% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

BWAY3 concerns · Avg: 2.3/10
Market CapQuality
$406.96M3/10

Smaller company, higher risk/reward

P/E RatioValuation
42.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.402/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 16.6% and operating margin at 19.6%. PEG of 0.76 suggests the stock is reasonably priced for its growth.

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Bear Case : BWAY

The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.

Key Dynamics to Monitor

BSX profiles as a value stock while BWAY is a growth play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.58 — expect wider price swings.

BWAY is growing revenue faster at 35.4% — sustainability is the question.

BSX generates stronger free cash flow (868M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (60/100 vs 51/100), backed by strong 16.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Want to dig deeper into these stocks?